A group of researchers has developed a new urine analysis for early detection of cervical cancer virus proteins, A test that offers a non -invasive alternative and that could encourage more women to submit periodic detections.
In depth
Cervical cancer is one of the most frequent among women, with approximately 660,000 new cases and 350,000 deaths around the world Only in 2022. Almost all cases are related to high -risk infections by human papillomavirus (HPV). Current screening methods consist of detecting HPV DNA, but new investigations suggest that measuring HPV cancer activity can provide a more precise evaluation of cancer risk.
Thus, scientists led by Professor Ethsuro Ito, from the Department of Biology at the University of Waseda (Japan), together with Professor Toshiyuki Sasagawa, of the Medical University of Kanazawa (Japan), and Dr. Martin Müller, of the German center of Oncological research (Germany), they investigated to develop An immunoenzymatic essay (‘Elisa’) Ultrasensitive to detect HP -TPH16 E7 high -risk oncoproteins in the urine. His findings have been published in the magazine ‘Microorganisms‘.
“Cancer can prevent yourself with vaccination before it develops and with periodic reviews. But screening is a great obstacle to young women. Our new urine analysis can detect HPV16 E7 proteins, which are critical markers of the risk of cervical cancer, at extremely low levels. This means that women could detect cervical cancer without the inconvenience and disadvantages of a traditional papasen test, “he explained Ito.
More details
Current cervical cancer detection methods usually consist of vaginal cytology or HPV DNA test, which require a visit to the doctor and can be uncomfortable for many women. This new urine analysis expects to offer a non -invasive alternative.
The researchers used ‘Elisa‘To detect oncoproteins E7 in urine samples. The test was able to identify these proteins in the urine of women with different stages of cervical intraepithelial neoplasia (NIC), precursor of cervical cancer. The ‘Elisa’ test detected E7 proteins in 80 percent of women with CIN1, 71 percent with CIN2 and 38 percent with CIN3, suggesting that the presence of Oncoproteins E7 correlates with lower degree CIN lesions. Researchers theorize that this discrepancy may be due to variations in the life cycle or the oncogenic activity of HPV.
“We believe that Oncoprotein E7 is fundamental in the early stages of cervical carcinogenesis related to HPV and that E7 can play a role most important in the progression of CIN1 and CIN2 than in CIN3“Ito said.
To take into account
This approach Innovative is in line with the world health objectives of reducing cervical cancer rates, especially in low and medium income countrieswhere access to traditional screening methods is limited.
According to the authors, with greater development and validation, this urine test could become a standard tool in the fight against cervical cancer, helping to save lives through an earlier detection and treatment.
For researchers, the development of a non -invasive urine analysis to detect HPV -related proteins represents an important step forward in the screening of cervical cancer and offers a promising solution for Increase screen rates and reduce the incidence of cervical cancer worldwide.
#Scientists #develop #urine #test #early #detection #cervical #cancer #virus #proteins
